NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Jazz Pharmaceuticals PLC JAZZ
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$4.3B
▲ 4.9% vs FY2024
EPS · FY25
$-5.84
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-8.5%
Net margin · FY25
-8.3%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 4.3B
Revenue, FY2025 · full 17-year series below
Revenue
Net income
The company lost 8 cents on every revenue dollar this year.
Per share
USD -5.84
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-8.5%
Return on equity, FY2025
ROE
Operating margin-10.1%
Net margin-8.3%
Return on assets-3.0%
Each USD of equity lost 8 cents this year.
Returned to shareholders
USD 125.0M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 125.0M
Share of profit-35.1%
Consecutive raises—
USD 125.0M in buybacks went back to shareholders in a year without profit.
Growth
+12.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+5.3%
+12.5%
+12.4%
+23.8%
Returned to shareholders
+1222.9%
−3.1%
+7.3%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.06B
Shares outstanding, FY2025
Change, 5 years+9.4%
Change, 10 years+0.2%
The share count grew 9% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 11.7B
total assets, end of FY2025
Total assetsUSD 11.7B
EquityUSD 4.3B
CashUSD 1.4B
Gross debtUSD 5.4B
Net debtUSD 4.0B
Current ratio1.86×
Net debt stands at 92% of equity.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
4.3
4.1
3.8
3.7
3.1
2.4
2.2
1.9
1.6
1.5
1.3
1.2
0.9
0.6
0.3
0.2
0.1
Operating income $B
−0.4
0.7
0.6
−0.1
0.2
0.4
0.5
0.6
0.5
0.6
0.5
0.2
0.3
0.2
0.1
0.1
0.0
EBITDA $B
−0.4
0.7
0.6
−0.0
0.2
0.4
0.5
0.6
0.5
0.6
0.5
0.2
0.3
0.2
0.1
0.1
0.0
Income tax $B
−0.3
−0.1
−0.1
−0.2
0.2
0.0
−0.1
0.1
−0.0
0.1
0.1
0.1
0.1
−0.1
0.0
0.0
·
Net income $B
−0.4
0.6
0.4
−0.2
−0.3
0.2
0.5
0.4
0.5
0.4
0.3
0.1
0.2
0.3
0.1
0.0
−0.0
EPS, diluted $
−5.84
8.65
6.10
−3.58
−5.52
4.22
9.09
7.30
7.96
6.41
5.23
0.93
3.51
4.79
2.67
0.83
−0.23
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−8.5
14.3
12.2
−6.4
−8.6
7.0
17.8
16.3
21.3
22.8
22.2
4.4
17.9
43.9
111.9
·
·
Shares out B
0.06
0.06
0.06
0.06
0.06
0.06
0.06
0.06
0.06
0.06
0.06
0.06
0.06
0.06
0.04
0.04
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
49 of 49
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed